Archives
-
From RNAi Findings to Spatially Resolved Validation
2026-10-04
A thought-leadership analysis of how fluorescent RNA probes can deepen interpretation of nanoparticle-mediated RNAi studies, with evidence boundaries, assay strategy, and the role of the HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit.
-
MLKL–Lysosome Signaling in Necroptosis
2026-10-03
The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a mechanistic step linking necrosome activation to cathepsin-dependent necroptosis. Its imaging, chemical perturbation, knockdown, and MLKL-domain evidence supports cathepsin B as an important contributor to cell death, while also defining limits for extrapolation to other death pathways and disease models.
-
15-PGDH Inhibition Protects Muscle During Weight Loss
2026-10-01
A 2026 PNAS study identifies 15-PGDH inhibition as a way to improve skeletal muscle repair and force recovery during semaglutide-associated weight loss in obese mice. The combination enhanced muscle stem cell activity and regenerated fiber growth without eliminating semaglutide’s weight-loss effect, providing a mechanistic framework for studying muscle preservation during GLP-1 receptor agonist treatment.
-
HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody
2026-10-01
A practical guide to using this Alexa Fluor 488 secondary antibody across immunofluorescence, Western blotting, flow cytometry, tissue staining, and ELISA. The workflow emphasizes species compatibility, signal amplification, controls, and translation of variant-vaccine findings into reproducible human-IgG assays.
-
Cy5 NHS ester(Et): Practical Labeling Guide
2026-10-01
Cy5 NHS ester(Et) is an amine-reactive fluorescent dye for covalently tagging proteins, peptides, and other biomolecules through primary amino groups. It is suited to fresh protein fluorescent labeling, immunofluorescence staining, flow cytometry, and fluorescence microscopy workflows, but ethanol-based preparation and long-term storage of working solutions should be avoided.
-
EZ Cap™ CPF1/Cas12a mRNA Guide
2026-09-30
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) is a Cas12a-encoding research reagent for mRNA-based genome-editing workflows. Its biological rationale is the Cas12a combination of T-rich PAM recognition, crRNA-guided targeting, and staggered DNA cleavage, while product-specific editing performance requires experimental validation.
-
Molidustat: From HIF Biology to Assay Design
2026-09-29
Molidustat (BAY85-3934) is a HIF-PH inhibitor that enables mechanistically resolved studies of erythropoietin stimulation and chronic kidney disease anemia. This article connects its oxygen-sensing pharmacology with VHL-dependent HIF-1α degradation and practical assay design.
-
Filipin III for Membrane Cholesterol Workflows
2026-09-29
Filipin III converts membrane cholesterol biology into an imaging- and fractionation-ready assay, with useful extensions from vesicle lysis to macrophage immunometabolism. This guide emphasizes practical controls, quantitative interpretation, and troubleshooting for membrane cholesterol visualization.
-
740 Y-P: PI 3-Kinase Activator Workflow
2026-09-28
740 Y-P is a cell-permeable PI 3-kinase activator for turning PI3K/AKT signaling into a measurable experimental variable. This guide translates its use across vesicular trafficking, cancer research, neuronal cell survival, and mitophagy-linked inflammation workflows, with practical handling and troubleshooting guidance.
-
Gap19 for Cx43 Signaling and Macrophage Assays
2026-09-28
Use Gap19 to probe Cx43-linked inflammatory signaling while preserving a key distinction: hemichannel inhibition is not the same as blocking gap junction channels. This practical workflow connects AngII-stimulated macrophage assays with neuroglial and ischemia research, while flagging where evidence is model-specific and optimization is essential.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-27
The study tests a localized tumor-suppressor replacement strategy: lipid nanoparticles deliver chemically modified p21 mRNA into bladder tumors. In cell and mouse models, p21 restoration was associated with cell-cycle suppression, apoptosis-related changes, and reduced orthotopic tumor growth, supporting further preclinical evaluation rather than establishing clinical efficacy.
-
AST 487: Practical RET Assay Design
2026-09-26
Use AST 487 to probe RET kinase signaling in models with verified RET activity—not as a stand-in for KDM4A inhibition. The distinction matters when translating a mesothelioma epigenetics study into a reproducible inhibitor workflow.
-
Machine Learning Predicts mRNA Vaccine LNP Formulations
2026-09-25
Wang and colleagues combined a LightGBM model, mouse experiments, and molecular dynamics to investigate lipid nanoparticle formulations for mRNA vaccines. Their model predicted formulation performance from a dataset of 325 samples and identified ionizable-lipid features associated with IgG responses, while experiments showed that performance depended on the tested formulation rather than on a universal lipid ranking.
-
DZNep Workflows for Epigenetic Research
2026-09-25
Use DZNep as a mechanistic perturbation to connect EZH2-associated chromatin changes with cell fate, AML apoptosis, or inflammatory readouts—not as a stand-in for targeted chromatin restoration. A controlled dose-and-time workflow helps separate these effects from broader methylation changes.
-
RG7388 and the p53 Response: Beyond Target Engagement
2026-09-24
RG7388 is an MDM2 antagonist that can probe how disruption of the MDM2–p53 interaction affects tumor-cell responses. This article connects its pharmacology to colorectal cancer research on MDM1, TP53 expression, and chemoradiotherapy sensitivity—while clarifying what the evidence does and does not establish.